Insulet Corporation (PODD)

NASDAQ: PODD · IEX Real-Time Price · USD
195.14
+0.18 (0.09%)
Jul 19, 2024, 12:03 PM EDT - Market open
0.09%
Market Cap 13.67B
Revenue (ttm) 1.78B
Net Income (ttm) 234.00M
Shares Out 70.04M
EPS (ttm) 3.33
PE Ratio 59.44
Forward PE 60.36
Dividend n/a
Ex-Dividend Date n/a
Volume 193,520
Open 197.01
Previous Close 194.96
Day's Range 194.09 - 198.59
52-Week Range 125.82 - 286.72
Beta 1.15
Analysts Buy
Price Target 238.81 (+22.38%)
Earnings Date Aug 8, 2024

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 15, 2007
Employees 3,000
Stock Exchange NASDAQ
Ticker Symbol PODD
Full Company Profile

Financial Performance

In 2023, Insulet's revenue was $1.70 billion, an increase of 30.02% compared to the previous year's $1.31 billion. Earnings were $206.30 million, an increase of 4384.78%.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $238.81, which is an increase of 22.38% from the latest price.

Price Target
$238.81
(22.38% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

11 days ago - Business Wire

Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared posi...

27 days ago - Business Wire

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

4 weeks ago - Business Wire

Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made severa...

4 weeks ago - Business Wire

Insulet to Present at the Jefferies Global Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...

7 weeks ago - Business Wire

Insulet misses first-quarter profit estimates as marketing costs weigh

Insulet Corp reported first-quarter profit that missed market expectations on Thursday, weighed by higher marketing expenses, sending shares of the medical device maker down 3.7% in extended trading.

2 months ago - Reuters

Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...

2 months ago - Business Wire

Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released it...

2 months ago - Business Wire

Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

3 months ago - Business Wire

Nadav Eiron Joins Crusoe as Senior Vice President of Cloud Engineering

SAN FRANCISCO--(BUSINESS WIRE)--Crusoe Energy Systems LLC (“Crusoe”) announced today that Nadav Eiron has joined the company as a Senior Vice President to lead the Cloud Engineering team in Crusoe's S...

3 months ago - Business Wire

Insulet Appoints Ana Maria Chadwick as Chief Financial Officer

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

4 months ago - Business Wire

Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented p...

4 months ago - Business Wire

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new ...

4 months ago - Business Wire

Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...

5 months ago - Business Wire

Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...

5 months ago - Business Wire

Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...

5 months ago - Business Wire

Insulet Announces Changes to Board of Directors with Retirements and New Appointments

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

6 months ago - Business Wire

Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...

6 months ago - Business Wire

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Other symbols: CIELVHUMINCYUNHXLVZTS
6 months ago - Market Watch

Ozempic and other weight-loss drugs' popularity set these stocks up for big gains

Investors have such high hopes for popular weight-loss medications like Wegovy and Ozempic, the wonder drugs have sent shock waves through the stock market.

7 months ago - Market Watch

Here are the 20 worst-performing stocks among the S&P 500 in 2023

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Other symbols: AESALBBMYCAGDGDVNEL
7 months ago - Market Watch

3 Medical-Device Stocks Could Click in 2024

Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.

Other symbols: BSXDXCM
7 months ago - Barrons

Salesforce, Insulet, and Datadog Are November's Top Performers—and These Are the Worst

Salesforce is the Dow Jones Industrial Average's top-performing stock in November, while Cisco is the worst.

Other symbols: CRMDDOG
8 months ago - Barrons

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...

8 months ago - Business Wire

Earnings-season winners: 20 companies that have grown sales while improving profit margins

Earnings season is a time when investors like to see a “beat and raise” pattern. That is, companies report sales and earnings that surprise the market by coming in ahead of analysts' estimates.

9 months ago - Market Watch